Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGAV | P06756 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895908 | 0.79 | HTT (0.45) | KDM4EAKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL1400599 | 0.78 | CTSA (0.39) | SMN1; SMN2AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL1813215 | 0.78 | IRAK4 (0.41) | LMNASMN1; SMN2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7230001 | 0.78 | CPB2 (0.44) | KDM4EAKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL6175456 | 0.77 | CCNT1 (0.40) | MAPK8AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL21392235 | 0.77 | CTPS1 (0.58) | CTPS1 | |
| SCHEMBL20487063 | 0.73 | KCNH2 (0.44) | KCNH2SCN5A | |
| SCHEMBL5791185 | 0.73 | FFAR1 (0.42) | KCNH2SCN5AITGB3ITGAV | |
| SCHEMBL29675928 | 0.72 | KCNH2 (0.40) | KCNH2SCN5ASMN1; SMN2ITGB1ITGA5 | |
| SCHEMBL6178948 | 0.71 | HSD11B1 (0.45) | KCNH2SCN5ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | KCNH2 3290/4885SCN5A 3591/4885LMNA 568/4885 |
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | KCNH2 2680/4885SCN5A 1018/4885LMNA 294/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | KCNH2 3342/4885SCN5A 3374/4885LMNA 3755/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | KCNH2 3290/4885SCN5A 3591/4885LMNA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.